Vivos (RDGL) Other Non-Current Liabilities (2013 - 2024)

Vivos (RDGL) reported Other Non-Current Liabilities of $40949.0 for Q4 2024, up 309.49% sequentially from $10000.0 in Q3 2023.

Vivos (RDGL) Other Non-Current Liabilities (2013 - 2024) Analysis & Trends

Vivos (RDGL) has 7 years of Other Non-Current Liabilities data on file, last reported at $40949.0 in Q4 2024.

For the quarter ending Q4 2024, Other Non-Current Liabilities changed N/A year-over-year to $40949.0; the trailing twelve-month figure through Dec 2024 stood at $40949.0 (changed N/A YoY), and the FY2024 full-year result was $40949.0, changed N/A from the prior year.
Other Non-Current Liabilities improved to $40949.0 in Q4 2024, from $10000.0 in the prior quarter.
In the past five years, Other Non-Current Liabilities ranged from a high of $40949.0 in Q4 2024 to a low of $10000.0 in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	182.32 Bn	175.02 Bn	6.27 Bn
2	Stryker	128.75 Bn	125.88 Bn	3.81 Bn
3	Medtronic	107.83 Bn	98.61 Bn	6.41 Bn
4	Boston Scientific	67.61 Bn	66.15 Bn	3.61 Bn
5	Edwards Lifesciences	48.13 Bn	44.45 Bn	1.29 Bn
6	Dexcom	28.26 Bn	27.14 Bn	750.30 Mn
7	GE HealthCare Technologies	27.78 Bn	25.50 Bn	1.98 Bn
8	Smith & Nephew	26.99 Bn	26.41 Bn	-
9	Koninklijke Philips	23.92 Bn	20.80 Bn	2.07 Bn
10	Vivos	27.16 Mn	25.60 Mn	-3,105.00

Download Data